Cellular uptake of habekacin, 1-N-(4-amino-2-hydroxybutyryl)dibekacin, was studied by incubating exponentially growing culture of Esclzerichia coli Q13 and its kanamycin-resistant mutants with [3H]habekacin. Kanamycin-resistant mutants, in which the resistance is due to alteration of ribosomes, were cross-resistant to habekacin, and showed a lower uptake of [3H]habekacin than the parental cells, suggesting that binding to ribosomes accelerates cellular uptake of habekacin. Cellular accumulation of [3H]habekacin by wild type cells was markedly inhibited by low temperature and by 2,4-dinitrophenol, suggesting that uptake of habekacin involves energy-dependent transport. The uptake of [3H]habekacin was reduced by various aminoglycoside antibiotics, suggesting common transport systems and/or common internal binding sites on the ribosome. Intracellular accumulation of [3H]dibekacin was reduced by habekacin, suggesting that both antibiotics possess a common transport system and/or common binding sites on the ribosome. Dibekacin was a better competitor than amikacin, suggesting that the dibekacin moiety of habekacin molecule, but not the 4-amino-2-hydroxybutyryl moiety, participates in the transport and/or binding to the ribosome. Binding of [3H]habekacin to E. coli ribosomes was reversed by various aminoglycosides and the degree of inhibition paralleled the one of cellular uptake, suggesting that competition by aminoglycosides for the habekacin uptake occurs at the ribosomal level.
Kanamycin-resistant mutants were isolated after treating Escherichia coli Q13 with N-methyl-N'-nitro-N-nitrosoguanidine8.9).
The resistance of R1-4, R2-1 and R3-3 mutants was attributed to alterations of the 30S ribosomal subunit, and that of R3-5 to a change in the 50S subunit.
Cellular uptake or accumulation of antibiotics was carried out by incubating [3H]habekacin or [3H]-dibekacin with E. coil cells in the logarithmic phase of growth. The cells were collected on Millipore filters and washed with phosphate-buffered saline, and radioactivity was assayed in a scintillation counter.
The binding of [3H]habekacin to E. coli ribosomes was determined by equilibrium dialysis as described previousl15).
Results

Uptake of [3H]
Habekacin by Sensitive and Resistant Cells of E. coli A culture of E. coli Q13 growing exponentially in nutrient broth was treated at zero time with
[3H]habekacin (2 pg/ml). The cells accumulated the antibiotic, and the kinetics of habekacin uptake were linear for 30 minutes with the initial binding followed by a lag period of several minutes (Fig. 2) .
In a similar experiment, uptake of habekacin occurred in the kanamycin-resistant mutants, R1-4, R2-1, [3H]Habekacin (2 pg/ml) was added to an exponentially growing culture of E. coil in nutrient broth at zero time.
E. coli Q13 (A). Kanamycin-resistant mutants: RI-4 (2), R2-1 (~), R3-3 (s), and R3-5 (•). The minimal inhibitory concentration was determined by agar streak method. The medium used was heart infusion agar (Difco).
Habekacin 1 ug/ mI=1.81 jim.
Time (minutes) OF ANTIBIOTICS MAY 1984 R3-3, and R3-5, to a much lower extent than in the sensitive parent strain (Fig. 2 ). All the resistant mutants, in which the resistance is attributed to alteration of the ribosomess. , displayed cross-resistance to habekacin (Table 1) . These results suggest that the binding to ribosomes accelerates cellular uptake of habekacin.
Effects [3H]Habekacin (2 ug/ml) was added at zero time to an exponentially growing culture of E. coli in nutrient broth.
Control (C). 2,4-Dinitrophenol was added to the mixture at zero time (•) or at 15 minutes (C). The culture was transferred to ice bath at zero time (•) or at 15 minutes (s).
Both procedures, introduced at zero time, resulted in the same degree of inhibition. The number represents relative uptake of [3H]-dibekacin, and 100 % uptake is 4.3 x 108 dibekacin molecules/cell. The exponentially growing cells of E. coli Q13 were incubated with 2 pM [3H]dibekacin at 37°C for 15 minutes in the presence or absence of habekacin, and transferred to ice bath. (Table 3 ). The results suggest that these antibiotics possess a common transport system or binding site on the ribosome.
Binding of [3H]Habekacin to E. coli Ribosomes in the Presence or
Absence of Various Aminoglycoside Antibiotics
The effects of various aminoglycosides on the binding of [3H]habekacin to E. coli ribosomes were then studied, and the results are summarized in Table 4 . The binding of habekacin was reduced by dibekacin, amikacin, kanamycin, streptomycin, or neomycin. The grade of inhibition by the aminoglycosides paralleled the one of cellular uptake ( Table 2 ). The results support the assumption that the competition by the aminoglycosides for the bacterial uptake of habekacin occurs at the ribosomal level.
Discussion
The current experiments provide evidence that transport systems and ribosomal binding sites of habekacin are common to other aminoglycoside antibiotics. The kinetics of habekacin uptake (Fig. 2 ) are in accordance with the model of three sequential phases (EIP, EDP-I and EDP-II) typical for other aminoglycosides8r. The effect of habekacin is less than that of dibekacin on [3H]habekacin uptake (Fig. 4) , suggesting a more (dibekacin) or less (amikacin) efficient competition for the same uptake channels and ribosomal binding sites. Competition by aminoglycosides for the cellular uptake of [3H]-habekacin may occur on the ribosome, because the degree of inhibition by the aminoglycosides of [3H]-habekacin binding to ribosomes was observed to parallel that of the cellular uptake.
From the viewpoint of cellular uptake and action on ribosomes, the present and previous" studies suggest that the antibacterial activity of habekacin is due to the dibekacin moiety of the molecule, and not to the 4-amino-2-hydroxybutyryl moiety. VOL. XXXVII NO. 5
